.jpg)
President, CSO, and Founder
VeroScience
Dr. Cincotta received his BA degree in biochemistry and molecular biology from The University of California, Santa Barbara and his Master of Science and PhD degrees in physiology with minor in biochemistry from Louisiana State University, Baton Rouge (LSU). He conducted postdoctoral studies simultaneously in both circadian neuroendocrine regulation of metabolism under the direction of Dr. Albert Meier at LSU and in photodynamic therapy of cancer for the late Dr. Edwin Land at the Rowland Institute for Science in Cambridge, MA. Following his postdoctoral training he joined the faculty at Harvard Medical School and staff at Massachusetts General Hospital (MGH) in the Department of Photomedicine to continue these research activities. Subsequent to his time at MGH, Dr. Cincotta founded both Ergo Science Corp. and then VeroScience LLC to advance clinical therapies for diabetes and cancer he helped develop in preceding years. He currently is the President and Chief Science Officer of VeroScience. His work has generated scores of peer reviewed publications in the fields of metabolism, chronobiology, and cancer research as well an equal number of issued US and international patents in these areas. Along with Dr. Meier, he is responsible for the invention of circadian timed bromocriptine-QR therapy (Cycloset®) for the treatment of type 2 diabetes and primarily responsible for all the developmental steps leading to its US FDA approval for this indication, currently owned by VeroScience. Cycloset is a first and only in-class sympatholytic dopamine agonist therapy marketed across the US for the treatment of type 2 diabetes.
Disclosure information not submitted.
Thursday, November 17, 2022
4:00 PM – 4:45 PM EST